CCR6 and idiopathic pulmonary fibrosis: Together, our findings demonstrate that augmentation of chemokines that recruit protective CCR4+ CD4+ T cells, while blocking chemokines that recruit detrimental CCR6+ CD4+ T cells, may constitute a novel approach for IPF therapy.